Clinicoradiographic predictors of progression of an intermediate hepatic lesion (LI-RADS 3) to hepatocellular carcinoma (LI-RADS 5)

Abstract

Aim: We sought to identify predictors of progression of an indeterminate observation (LI-RADS 3) to hepatocellular carcinoma (LI-RADS 5).

Methods: Imaging reports with LI-RADS (LR) assignments were identified among patients at the University of Washington, 2013-2017. Patients with an LR3 lesion and follow-up scan within 1 year of LR3 lesion date were included (n = 313). Features of interest were abstracted from chart review. Survival analyses employing interval censoring were performed, with variables potentially predictive of LR3 progression identified in univariate analyses. Backwards elimination (P < 0.05) was used to obtain the final multivariate model.

Results: 20.4% of LR3 lesions progressed to LR5; 73% remained LR3, 8% LR4. The cohort was predominantly male (61%), Caucasian (54%), older than 55 (63%). 47% had a history of hepatitis C virus (HCV), 33% with alcohol abuse, not mutually exclusive. Alpha-fetoprotein (AFP) at the time of LR3 scan was low if available (39% with AFP < 5, 29% unknown). CT was the most common exam (56%). Men (HR = 2.0, P = 0.02), earlier scan year (HR = 0.47 per year, P < 0.0001), and older age (HR = 1.48, P = 0.03), appeared as predictors of LR progression in the final model. HCV and alcohol use were more common among men but did not appear to explain the difference in LR progression by sex.

Conclusion: Our analysis is an early exploration of characteristics that may predict the risk of progression of an LR3 observation to hepatocellular carcinoma. Future efforts may allow for risk stratification to identify high-risk indeterminate lesions that may benefit from earlier intervention or more frequent surveillance.

Keywords

LI-RADS / hepatocellular carcinoma / liver imaging

References

[1] Marks RM,Chernyak V.LI-RADS: past, present, and future, from the AJR special series on radiology reporting and data systems.AJR Am J Roentgenol2021;216:295-304

[2] Cunha GM,Abushamat F,Kono Y.Imaging diagnosis of hepatocellular carcinoma: the liver imaging reporting and data system, why and how?.Clin Liver Dis2020;24:623-36

[3] Ren AH,Yang DW,Wang ZC.Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.J Magn Reson Imaging2019;50:746-55

[4] Chernyak V,Kamaya A.Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients.Radiology2018;289:816-30 PMCID:PMC6677371

[5] Marrero JA,Sirlin CB.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases.Hepatology2018;68:723-50

[6] Hong CW,Mamidipalli A.Longitudinal evolution of CT and MRI LI-RADS v2014 category 1, 2, 3, and 4 observations.Eur Radiol2019;29:5073-81 PMCID:PMC7495398

[7] Bruix J,Mazzaferro V.Hepatocellular carcinoma: clinical frontiers and perspectives.Gut2014;63:844-55 PMCID:PMC4337888

[8] Johnson PJ,Kagebayashi C.Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.J Clin Oncol2015;33:550-8 PMCID:PMC4322258

[9] Kierans AS,Gavlin A.Diagnostic performance of LI-RADS version 2018, LI-RADS version 2017, and OPTN criteria for hepatocellular carcinoma.AJR Am J Roentgenol2020;215:1085-92

[10] Elsayes KM,Chernyak V.LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance.J Hepatocell Carcinoma2019;6:49-69 PMCID:PMC6368120

[11] Elsayes KM,Agrons MM.Liver Imaging Reporting and Data System: an expert consensus statement.J Hepatocell Carcinoma2017;4:29-39 PMCID:PMC5322844

[12] Russo MW.Radiological diagnosis of hepatocellular carcinoma.Clin Liver Dis (Hoboken)2012;1:190-3 PMCID:PMC6499298

[13] The American College of Radiology LI-RADS v2017 Core. Available from: https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/Ultrasound-LI-RADS-v2017 [Last accessed on 10 Dec 2021]

[14] Kielar AZ,Bashir MR.LI-RADS 2017: an update.J Magn Reson Imaging2018;47:1459-74 PMCID:PMC6652220

[15] The American College of Radiology LI-RADS v2018 Core. Available from: https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf?la=en [Last accessed on 10 Dec 2021]

[16] Elmohr M,Chernyak V.LI-RADS: review and updates.Clin Liver Dis (Hoboken)2021;17:108-12 PMCID:PMC8043699

[17] Kanmaniraja D.Liver imaging reporting and data system and CT/MRI diagnosis of hepatocellular carcinoma.Hepatoma Res2020;6:51

[18] Liu P,Hu S.Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States.Oncotarget2017;8:68131-7 PMCID:PMC5620243

[19] Lafaro KJ,Pawlik TM.Epidemiology of hepatocellular carcinoma.Surg Oncol Clin N Am2015;24:1-17

[20] Shimizu I.Protection of estrogens against the progression of chronic liver disease.Hepatol Res2007;37:239-47

[21] McGlynn KA,Campbell PT.Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project.Br J Cancer2015;112:1266-72 PMCID:PMC4385955

[22] Singal AK.Mechanisms of synergy between alcohol and hepatitis C virus.J Clin Gastroenterol2007;41:761-72

[23] Shropshire E,Wolfson T.LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study.Abdom Radiol (NY)2020;45:3092-102

[24] Cannella R,Celsa C.Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals.Liver Int2021;41:2179-88

[25] Ojeda PI,Mieloszyk RJ.Is there a difference between LI-RADS 3 to LI-RADS 5 progression assessment using CT versus MR?.Curr Probl Diagn Radiol2021;